Efficacy of multidrug superselective intra-arterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer
Authors:
- Tohru FurusakaTFTohru Furusaka
- Takeshi AsakawaTATakeshi Asakawa
- Akane TanakaAkane Tanaka
- Hiroshi MatsudaHMHiroshi Matsuda
- Minoru IkedaMIMinoru Ikeda
- 12 June 2012
- journal article
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 132 (10) , 1108-1114
Abstract
This therapy produced better results than intravenous multidrug chemotherapy (CF therapy, CPF therapy, etc.) or superselective intra-arterial chemotherapy (SIC) alone with cisplatin (CDDP) and 5-fluorouracil (5-FU). Primary tumor may be controlled by SIC alone in cases of T2 and many cases of T3 tumors, and by the combination of SIC and concurrent radiotherapy in cases of T3 and many cases of T4a. Cervical lymph node metastasis was treated with neck dissection in some patients. The results indicate that this therapy is useful to control primary tumor without resection for organ preservation. This therapy was intended to control primary tumor without resection for better quality of life (QOL). A total of 45 patients with primary squamous cell carcinoma of the tongue were included in the study. SIC with docetaxel, cisplatin, and 5-FU was administered. In terms of the primary response of primary tumor, 43 patients achieved a clinical complete response (CR). Moreover, in these patients no cancer cells were histopathologically found by biopsy, resulting in a response rate of 100% and a CR rate of 95.6%. During the median follow-up period of 1779 days (59 months) (range 110-3752 days), the 5-year survival rate and organ preservation rate were 89.8% and 80.7%, respectively.Keywords
This publication has 6 references indexed in Scilit:
- Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck CancerNew England Journal of Medicine, 2007
- Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck CancerNew England Journal of Medicine, 2007
- Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil–cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neckAnti-Cancer Drugs, 2004
- Combination Chemotherapy with CDDP and 5-FU in Head and Neck CancerAuris Nasus Larynx, 1986
- Combination Chemotherapy with CDDP, 5-FU and Pep in Head and Neck Malignant TumorsAuris Nasus Larynx, 1986
- Cap Therapy for Advanced, Recurrent and/or Metastatic Malignant Tumors of the Head and NeckAuris Nasus Larynx, 1986